Home>Topics>>Therapeutic Proteins Offer New Investment Opportunities
Therapeutic Proteins Offer New Investment Opportunities
Healthcare Sector and Stocks Analysis from Seeking Alpha
Sat, 24 Nov 2012
By Cris Frangold : A few days ago, Prolor Biotech ( PBTH ) was downgraded by research analysts at Summer Street from a "buy" rating to a "sell" rating. Summer Street now has a $3.00 target price on the stock, down from their previous target price of $6.00. The stock is trading at around $4.42 with ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.